Frédéric Y. Bois

hideThis article has multiple issues. Please help or discuss these issues on the talk page. (Learn how and when to remove these template messages) This biographical article is written like a résumé. Please by revising it to be neutral and encyclopedic. (August 2019) This article is an autobiography or has been extensively edited by the subject or by someone connected to the subject. It may need editing to conform to Wikipedia's neutral point of view policy. There may be relevant discussion on the talk page. (August 2019) (Learn how and when to remove this template message) The topic of this article may not meet Wikipedia's notability guideline for biographies. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources:  –  ·  ·  · scholar · JSTOR (August 2019) (Learn how and when to remove this template message) This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. Please help by replacing them with more appropriate citations to reliable, independent, third-party sources. (August 2019) (Learn how and when to remove this template message) (Learn how and when to remove this template message)

Frederic Y. Bois
Born	1958 (age 62–63)
Nationality	French
Alma mater	Paul Verlaine University – Metz, France
Known for	Pharmacokinetics Bayesian Statistics
Awards	American Statistical Association "Outstanding Statistical Application Award" French Epidaure Prize for Environmental Health Research National Order of Merit (France) Ordre des Palmes Académiques
Scientific career
Fields	Systems Toxicology
Institutions	CERTARA, Simcyp division

Frédéric Yves Bois, Pharm.D.Ph.D. (born 1958) is a French biological scientist working in toxicology and bioinformatics.^[1][2] He is currently Research Director at the French Institut National de l'Environnement et des Risques (INERIS).

Biography[]

Frédéric Bois was born in Limoges, France, in 1958. He obtained his Pharm.D. from the Université de Nancy (1981) and his Ph.D. from the University of Metz (1988). Most of his Ph.D. thesis, on the use of physiologically based pharmacokinetic models and models for risk assessment, was developed at the Harvard University Energy and Environmental Policy Center (in Richard Wilson's group at the Jefferson Physical Laboratory). His post-doctoral research was performed at UCSF and UC Berkeley School of Public Health. He then held joint appointments at the California Environmental Protection Agency (under the direction of Dr. Lauren Zeise) and the Lawrence Berkeley National Laboratory (in the group of Dr. Joan Daisey). Upon his return to France he worked at INSERM (in the group of Pr. A.-J. Valleron) until 1998. He was Research Director at the INERIS research lab from 1999 to 2019. From 2009 to 2015 he was also incumbent of Chair of Mathematical Modelling for Systems Toxicology of the Université de Technologie de Compiègne. He is now Senior Scientific Advisor in the Simcyp division of the Certara Company.^[3] He is married to Nicole Cancré and they have four children: Pauline, Jules, Eugène and Camille.

He is member of the French fr:Comité de la prévention et de la précaution,^[1] scientific editor for "In Silico Pharmacology"^[4] and "Environnement, Risque et Santé"^[5]

Work[]

Frédéric Y. Bois has worked at the Energy and Environmental Policy Center at Harvard University (1985-1987), in the research group of Pr. Richard Wilson (Jefferson Laboratory) during his PhD thesis. His work focused on physiologically based pharmacokinetic (PBPK) modeling and stochastic cancer models, applied to vinyl chloride. He then worked as a post-doctoral scientist at the University of California, San Francisco School of Pharmacy with Pr. Thomas Tozer (1988) and at the University of California, Berkeley School of Public Health (1989), focusing on Monte-Carlo based uncertainty analysis of PBPK models. During a joint appointment at the California Environmental Protection Agency and at the Lawrence Berkeley National Laboratory he developed, in collaboration with Andrew Gelman, the application of Bayesian numerical approaches to multilevel PBPK models. He directed several research projects for the US Food and Drug Administration, the National Institute of Health, the Environmental Protection Agency, and the Occupational Safety and Health Administration. He contributed mostly to the fields of bioequivalence testing, health risk assessment,^[6] population pharmacokinetics and Bayesian statistics. He is the developer, together with D. Mazsle, of the GNU MCSim software.

He is currently Research Director at the Institut national de l'environnement industriel et des risques (INERIS) where he coordinated to the European integrated project 2FUN (https://web.archive.org/web/20131028035939/http://www.2-fun.org/), and participated to several others (ACUTEX, NANOSAFE 2, PREDICT-IV, StemBANCC). His recent work is on Physiologically based pharmacokinetic modelling, bioinformatics and systems biology.

He is member or past member of US National Research Council Standing Committee on Risk Analysis Issues and Reviews,^[7] the American Association for the Advancement of Science, the Society for Mathematical Biology, the European Science Foundation-EERO Association, the French Statistical Society, the French National Association for Technological Research. He is a recipient of the American Statistical Association "Outstanding Statistical Application Award"^[8] and of the French Epidaure Prize for Environmental Health Research.

Positions and awards[]

• 1984 Fall: Visiting Scientist, Division of Environmental Carcinogenesis, International Agency for Research on Cancer, Lyon, France.
• 1986-87: Research Associate, Energy and Environmental Policy Center, Harvard University, Cambridge, USA.
• 1987-88: Post-Doctoral Research Biologist, University of California Medical Center, San Francisco, USA.
• 1988-90: Post-Graduate Researcher VII, School of Public Health, University of California, Berkeley, USA.
• 1991-96: Staff Toxicologist (Specialist), Reproductive and Cancer Hazard Assessment Section, California Environmental Protection Agency, Berkeley, USA.
• 1991-99: Staff Scientist, Lawrence Berkeley Laboratory, Berkeley, USA.
• 1992-93: Maître de Conférence Associé, Faculté des Sciences Pharmaceutiques et Biologiques, Université de Nancy, France.
• 1996: October–December: Visiting Professor, School of Public Health, University of California, Berkeley, USA.
• 1995-99: Visiting Scientist, Unité INSERM 444 (Biomathématiques, Biostatistiques et Epidémiologie), Paris.
• 1999: Visiting Scientist, Lawrence Berkeley Laboratory, Berkeley, USA.
• 1999-2000: Research Scientist, INERIS, Verneuil en Hallate, France.
• 2000-04: Head of the Experimental Toxicology Laboratory, INERIS, Verneuil en Hallate, France.
• 2002: Knight, National Order of Merit (France)
• 2009-2015: Professor, Chair of Mathematical Modelling for Systems Toxicology, UTC, Compiègne, France.
• 2004-: Scientific Officer, Division of Chronic Risks, INERIS, Verneuil en Hallate, France.
• 2017: Knight, Ordre des Palmes Académiques (France)

Major Publications[]

• Bois F., Golbamaki-Bakhtyari N., Kovarich S., Tebby C., Gabb H.A., Lemazurier E., 2017, A high-throughput analysis of ovarian cycle disruption by mixtures of aromatase inhibitors, Environmental Health Perspectives, 077012-1, doi:10.1289/EHP742.
• Gould A.L., Boye M.E., Crowther M.J., Ibrahim J.G., Quartey G., Micallef S., Bois F., 2015, Joint Modeling of Survival and Longitudinal Non-Survival Data: Current Methods and Issues. Report of the DIA Bayesian Joint Modeling Working Group [with discussion]. Statistics in Medicine, 34:2181-2203, doi:10.1002/sim.6141.
• Bois F., Gayraud G., 2015, Probabilistic generation of random networks taking into account information on motifs occurrence, Journal of Computational Biology, 22:25-36, doi:10.1089/cmb.2014.0175.
• Hamon J., Jennings P., Bois F., 2014, Systems biology modeling of omics data: effect of cyclosporine a on the Nrf2 pathway in human renal cells. BMC Systems Biology 8:76, doi: 10.1186/1752-0509-8-76.
• Wilmes A., Limonciel A., Aschauer L., Moenks K., Bielow C., Leonard M.O., Hamon J., Carpi D., Ruzek S., Handler A., Schmal O., Herrgen K., Bellwon P., Burek C., Truisi G.L., Hewitt P., Di Consiglio E., Testai E., Blaauboer B.J., Guillou C., Huber C.G., Lukas A., Pfaller W., Mueller S.O., Bois F., Dekant W., Jennings P., 2013, Integrated omic profiling reveals novel insights of cyclosporine A induced cellular stress, Journal of Proteomics, 79:180-194, doi: 10.1016/j.jprot.2012.11.022.
• Zeise L., Bois F., Chiu W.A., Hattis D.B., Rusyn I., Guyton K.Z., 2013, Addressing human variability in next generation health assessments of environmental chemicals, Environmental Health Perspectives, 121:23-31, doi: 10.1289/ehp.1205687.
• Bois F., 2012, Bayesian inference, in Computational Toxicology vol. II, Reisfeld B., Mayeno A.N. Eds., Methods in Molecular Biology Series, 930:597-636, Humana Press, New-York, doi: 10.1007/978-1-62703-059-5_25.
• Cheng S., Bois F., 2011, A mechanistic modeling framework for predicting metabolic interactions in complex mixtures, Environmental Health Perspectives, 119:1712-1718.
• Adler S., Basketter D., Creton S., Pelkonen O., van Benthem J., Zuang V., Ejner Andersen K., Angers-Loustau A., Aptula A., Bal-Price A., Benfenati E., Bernauer U., Bessems J., Bois F., et al., 2011, Alternative (non-animal) methods for cosmetics testing: current status and future prospect - 2010, Archives of Toxicology, 85:367-485.
• Bois F., Jamei M., Clewell H.J., 2010, PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals, Toxicology, 278:256-267.
• Bois F., 2010, Physiologically-based modelling and prediction of drug interactions, Basic and Clinical Pharmacology and Toxicology, 106¬†:154-161, doi: 10.1111/j.1742-7843.2009.00488.x.
• Bois F., 2009, GNU MCSim: Bayesian statistical inference for SBML-coded systems biology models, Bioinformatics, 25:1453-1454, doi: 10.1093/bioinformatics/btp162.
• Brochot C., Smith T.J., Bois F., 2007, Development of a physiologically based toxicokinetic model for butadiene and four major metabolites in humans: Global sensitivity analysis for experimental design issues, Chemico-Biological Interactions, 167:168-183.
• Amzal B., Bois F., Parent E., Robert C.P., 2006, Bayesian optimal design via interacting MCMC, Journal of the American Statistical Association, 101:773-785.
• Chiu W.A., Bois F., 2006, Revisiting the population toxicokinetics of tetrachloroethylene, Archives of Toxicology, 80:386-.
• Brochot C., Toth J., Bois F., 2005, Lumping in pharmacokinetics, Journal of Pharmacokinetics and Pharmacodynamics, 32:719-736.
• Brochot C., Bessoud B., Balvay D., Cuenod C.-A., Siauve N., Bois F., 2004, Bayesian physiologically based pharmacokinetic modeling of tumors' microcirculation magnetic resonance imaging data: Application to the evaluation of an antiangiogenic treatment, Toxicology and Applied Pharmacology 197(3):365-365. (non refereed)
• Mezzetti M., Ibrahim J.G., Bois F., Ryan L.M., Ngo L., Smith T.J., 2003, A Bayesian compartmental model for the evaluation of 1,3-butadiene metabolism, Journal of the Royal Statistical Society, Series C, 52:291-305.
• Bernillon P., Bois F., 2000, Statistical issues in toxicokinetic modeling: A Bayesian perspective, Environmental Health Perspectives, 108(suppl.5):883-893.
• Cancré N., Tall A., Rogier C., Faye J., Sarr O., Trape J., Bois F., 2000, Bayesian analysis of an epidemiological model of P. falciparum malaria infection in Ndiop, Senegal, American Journal of Epidemiology, 152:760-770.
• Bois F., 2000, Statistical Analysis of Fisher et al. PBPK model of trichloroethylene kinetics, Environmental Health Perspectives, 108(suppl. 2):275-282.
• Bois F., 2000, Statistical Analysis of Clewell et al. PBPK model of trichloroethylene kinetics, Environmental Health Perspectives, 108(suppl. 2):307-316.
• Bois F., 1999, Analysis of PBPK models for risk characterization, Annals of the New York Academy of Sciences, 895:317-337.
• Bois F., Smith T., Gelman A., Chang H.‚ÄëY., Smith A., 1999, Optimal design for a study of butadiene toxicokinetics in humans, Toxicological Sciences, 49:213-224.
• Bois F., Fahmy T., Block J.C., Gatel D., 1997, Dynamic modeling of bacteria in a pilot drinking water distribution system, Water Research, 31:3146-3156.
• Gelman A., Bois F., 1997, Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials - Comment, Journal of the American Statistical Association, 92:1248-1250.
• Gelman A., Bois F., Jiang J., 1996, Physiological pharmacokinetic analysis using population modeling and informative prior distributions, Journal of the American Statistical Association, 91:1400-1412.
• Bois F., Jackson E., Pekari K., Smith M., 1996, Population toxicokinetics of benzene, Environmental Health Perspectives, 104(suppl. 6):1405-1411.
• Tozer T.N., Bois F., Hauck W.H., Chen M.-L., Williams R., 1996, Absorption rate vs. exposure: Which is more useful for bioequivalence testing?, Pharmaceutical Research, 13:453-456.
• Bois F., Gelman A., Jiang J., Maszle D., Zeise L., Alexeef G., 1996, Population toxicokinetics of tetrachloroethylene, Archives of Toxicology, 70:347-355.
• Bois F., Krowech G., Zeise L., 1995, Modeling human interindividual variability in metabolism and risk: The example of 4-aminobiphenyl, Risk Analysis, 15:205-213.
• Thouand G., Friant P., Bois F., Cartier A., Maul A., Block J.C., 1995, Bacterial inoculum density and probability of para-nitrophenol biodegradability test response, Ecotoxicology and Environmental Safety, 30:274-282.
• Spear R., Bois F., 1994, Parameter variability and the interpretation of physiologically based pharmacokinetic modeling results, Environmental Health Perspectives, 102(suppl. 11):61-66.
• Bois F., Tozer T.N., Hauck W.H., Chen M.-L., Patnaik R., Williams R., 1994, Bioequivalence: Performance of several measures of rate, Pharmaceutical Research, 11:966-974.
• Bois F., Tozer T.N., Hauck W.H., Chen M.-L., Patnaik R., Williams R., 1994, Bioequivalence: Performance of several measures of extent, Pharmaceutical Research, 11:715-722.
• Maszle D., Bois F., 1993, Program MCSim - User Manual, Simulation program developed and distributed for Unix, Microsoft DOS, and Macintosh platforms.
• Woodruff T., Bois F., Auslander D., Spear R., 1992, Structure and parametrization of toxicokinetic models: Their impact on model predictions, Risk Analysis, 12:189-201.
• Bois F., Woodruff T., Spear R., 1991, Comparison of three physiologically-based pharmacokinetic models of benzene disposition, Toxicology and Applied Pharmacology, 110:79-88.
• Bois F., Smith M., Spear R., 1991, Mechanisms of benzene carcinogenesis: Application of a physiological model of benzene pharmacokinetics and metabolism, Toxicology Letters, 56:283-298.
• Bois F., Gravil P.J., Vasseur P., Isoard P., 1988, Optimal pollution control strategies in the presence of interacting toxicants, Water Research, 22:1443-1447.
• Bois F., 1988, Modelisation Mathematique de la Cancérogenèse par des Produits Chimiques, 130 p. with appendices, Ph.D. thesis. Universite de Metz, Mention Sciences, Metz.

References[]

External links[]

• INERIS/DRC/VIVA/METO webpage
• Comité de la Prévention et de la Précaution
• INERIS Website